EUREKA Registry

The purpose of this „European survey on the assessment of deep molecular response in chronic phase CML patients after at least two years of therapy with tyrosine kinase inhibitors (EUREKA)“ lab registry is to collect data on the standardized assessmant of molecular response in the context of real life clinical practice.

Based on the importance of the molecular response in the context of CML management and prognosis, accurate and reproducible molecular analyses are essential for physicians to make clinical decisions and refine treatment options. For example, the loss of a previously achieved MMR is indicative of a potential need for treatment change, as it may be related to a re-activation of the disease or the emergence of treatment-resistant mutations.

Eligible patients have been treated with one or more TKIs for a minimum of 24 months at registry entry. According to current recommendations (Baccarani et al 2013), achieving a major molecular response (MMR) following 12 months treatment is considered an optimal response to therapy. Patients treated for at least 24 months are therefore most likely to have deeper molecular responses that require detection using a sensitive assay.